Navigation Links
Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research

s may require closer monitoring -- The most common adverse reactions in patients with stage II or III colon cancer receiving adjuvant therapy were peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, emesis, fatigue, and stomatitis. The most common adverse reactions in patients with advanced colorectal cancer were peripheral sensory neuropathy, fatigue, neutropenia, nausea, emesis, and diarrhea

For more information about Eloxatin(R) or for full prescribing information, including BOXED WARNING, visit http://www.eloxatin.com.


    About Taxotere(R)

    Indications and Usage

Breast Cancer

Taxotere(R) is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.

Taxotere(R) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.

Non-Small Cell Lung Cancer (NSCLC)

Taxotere(R), as a single agent, is indicated for the treatment of patients with locally advanced or metastatic NSCLC after failure of prior platinum- based chemotherapy.

Taxotere(R) in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic NSCLC who have not previously received chemotherapy for this condition.

Prostate Cancer

Taxotere(R) in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer.

Gastric Cancer

Taxotere(R) in combination with cisplatin and flourouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:11/26/2008)...swire/ -- Children whose eyes are misaligned and p...f developing mental illness by early adulthood, ac...hed this month in Pediatrics , the official journa... The retrospective study examined the medical rec...yes) and compared them with records of children ma...
(Date:11/25/2008)... , Audio and Web Video Resources to accompany ...log. Please see the bottom of this release for det...RNewswire-USNewswire/ -- A Mayo Clinic study shows... having a stroke -- and as a result -- delay seeki...ndings appear in the current issue of Emergency Me...
(Date:11/25/2008)...swire/ -- Proteolix, Inc., a,leader in the discov...get,protein degradation pathways in cancer and au... two ongoing Phase 2 clinical trials of carfilzomi...coming 50th Annual Meeting of the,American Societ...n a new class,of specific proteasome inhibitors a...
(Date:11/25/2008)...Assess Survival of Patients Receiving Litx versus ...cellular Carcinoma , , BELLEVUE, Wash., Nov... (LSO) today announced the completion of enrollmen...sion Therapy(TM) (Litx(TM)) as a treatment for unr...wn as hepatoma or primary liver cancer. , , ...
Breaking Medicine Technology:Eye Divergence in Children Triples Risk of Mental Illness 2Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Iomai CEO to Speak at BIO CEO 26 Investor Forum on Feb 12 3065 1Iomai CEO to Speak at BIO CEO 26 Investor Forum on Feb 12 3065 2Tourtellotte Solutions Fusion DMC 28TM 29 Unifies the World of Bio Pharma Documents 11110 1Tourtellotte Solutions Fusion DMC 28TM 29 Unifies the World of Bio Pharma Documents 11110 2Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies 3064 1Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies 3064 2Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies 3064 3Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 1Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 2Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 3Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 4Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 5Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 6Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 7Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 8
...--(BUSINESS WIRE)--Jun 6, 2007 - Inovio Biomedical...t of DNA vaccines,for cancers and infectious disea...calized cancers, announced today the company,deliv...esults and,new device innovations relating to its ...t the 10th Annual Meeting of the American,Society ...
...fficacy and Markers Demonstrated in Combination Tr...stCall/ --,EntreMed, Inc. , a clinical-stage pharm...y for the treatment of cancer and inflammatory,dis...from the Phase,1b study with Panzem(R) NCD (2ME2 o... (paclitaxel) in patients with metastatic,breast c...
Other Medicine Technology:Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting 2Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting 3Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting 4Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting 5Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer,Study Presented at ASCO 2Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer,Study Presented at ASCO 3Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer,Study Presented at ASCO 4
(Date:12/2/2008)...stCall/ -- Genoptix, Inc. (Nasdaq: GXDX ), a spe...nced the Company,s participation at the RBC Capita...take place at the Westin New York Hotel at Times S...ccitelli, COO and executive vice president of Geno...conference on Wednesday, December 10, beginning at...
(Date:12/2/2008).../ -- LCA-Vision Inc. (Nasdaq:, LCAV ), a leading...r the,LasikPlus(R) brand, today announced that me...nt at RBC Capital Markets, 2008 Healthcare Confere...astern time. The conference is,being held at The... archived,webcast of the event will be available ...
(Date:12/2/2008)... -- In response to the commentary entitled "Cod Li...Infections, and the Vitamin D Deficiency Epidemic"...ement experts, Nordic Naturals announced today tha...promise to consumers and actually offer healthy om...itamin A. According to Karin Yien, MD, Nordic Natu...
(Date:12/2/2008)...hcare group at Frost & Sullivan,( http://www....t it will be,hosting an interactive analyst brief... on 11 December 2008 at 3pm GMT. , (Logo: ...O ) , With most diagnostic cardiology marke...are faced with an immense challenge of keeping pro...
Breaking Medicine News(10 mins):Health News:Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference 2Health News:Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy 2Health News:Will Diagnostic Cardiology Vendors Look to Product Innovation? 2
...in Andhra Pradesh have hit on a novel method of pr...n thousands of residents opened their// newspapers...three condoms on the front page. "Earlier we dist..., through milk vendors and at pan (tobacco) shops ...
...ticals, a leading player in the Indian drug indust...d and Drug Authority (FDA) for three// of its abbr...me. Orchid will be launching this product in the... partner, Apotex, the Chennai-based company said i...
...ts are high in saturated and trans fats, a high in...ed rate of decline in thinking, learning// and mem... essential for brain development and function, an ...ole in the development of brain plaques associated...
...British Medical Journal, researchers at Oxford Uni...er cent in the consumption of common foods// conta...increase in coronary heart disease. Trans fats ar...shelf life of food and is added to most fast foods...
Other Medicine News:Health News:High-Fat, Copper-Rich Diets Associated with Increased Rates of Cognitive Decline 2
Universal vacuum pump (capacity 34 L/min, 8 mbar vacuum abs.)
...es BchiVac V-500 with Vacuum Controller V-800 Ef... switching mechanism turns V-500 on and off as nee...ing Model V-500 is a powerful PTFE membrane vacu...s. Applications Ideally suited for use with up ...
...1000 is a new addition to the powerful PTFE membra...ce pump can achieve an ultimate vacuum of 1 mbar o... with vacuum drying ovens and centrifugal vacuum c...size up to industrial size rotary evaporators Bchi...
...500 is a powerful PTFE membrane vacuum pump design...ns Ideally suited for use with up to two rotary ...ents including vacuum ovens, concentrators, gel dr...es PEEK head resistant to chemicals and heat load...
Medicine Products: